- Sales Increase 16.3%
- Diluted Earnings Per Share (non-GAAP) Increase 15%
- Improved Cash and Financing Positions by $20 million
- 19% Growth in Sales of Minimally Invasive Camera Systems
UTICA, N.Y., April 28 /PRNewswire-FirstCall/ -- CONMED Corporation
(Nasdaq: CNMD) announced today its financial results for the first quarter of
2005.
Mr. Joseph J. Corasanti, President and Chief Operating Officer, commented,
"Our first quarter 2005 results were in-line with our expectations thanks to
the continued strong performance of our operating divisions. Of note, our
minimally invasive camera systems and powered surgical instruments had
particularly strong sales for the quarter thanks to sustained growth in
revenues from sales of our new camera system and our PowerPro(TM) line of
powered surgical instrument handpieces and single-use attachments.
Additionally, during the quarter, we launched seven new products at the annual
conference of the American Academy of Orthopaedic Surgeons (AAOS) in
Washington D.C. which were well-received by the marketplace."
Total sales for the first quarter increased 16.3% to $155.9 million
($154.1 million at constant exchange rates) compared to $134.0 million in the
first quarter of 2004. The previously announced acquisition of the Endoscopic
Technologies business on September 30, 2004 added $14.3 million to sales for
the first quarter of 2005. Excluding acquisition and other charges (please
see attached reconciliation for full explanation), non-GAAP net income for the
first quarter grew to $13.5 million, or $0.46 per diluted share, compared to
$12.0 million (GAAP), or $0.40 per diluted share, in last year's first
quarter. GAAP net income, including acquisition and transition charges, for
the three months ended March 2005 was $10.8 million, or $0.36 per diluted
share.
Following is a summary of first quarter sales by product line in millions
of dollars:
Three Months
Ended March, Percent
2004 2005 Increase
Orthopaedic Surgery
Arthroscopy $50.3 $53.6 6.6%
Powered Surgical Instruments 33.5 35.5 6.0%
Integrated Systems 1.0 0.4 -
84.8 89.5 5.5%
General Surgery and Patient Care
Electrosurgery 20.2 20.9 3.5%
Patient Care 18.0 18.9 5.0%
Endosurgery 11.0 12.3 11.8%
Endoscopic Technologies -- 14.3 --
49.2 66.4 35.0%
Total $134.0 $155.9 16.3%
Arthroscopy product growth continues to be led by sales of minimally-
invasive surgery camera systems, which increased 19% over the first quarter of
2004. This growth is being driven by sales of the enhanced definition camera,
introduced early in 2004, which has superior resolution capabilities, enabling
it to compete effectively for not only arthroscopy applications, but also
general surgical applications. Powered Surgical Instruments had continued
strong growth of the large bone products which grew 9% from last year's first
quarter, while the small bone and specialty products increased slightly
compared to the prior year's first quarter, as expected.
Electrosurgery and Patient Care had good growth rates due to improved
sales of single-use disposable products. The pulse oximetry line introduced
in 2004 continued to progress in the first quarter, achieving sales of
approximately $1.1 million for the three months. The Endosurgery business had
strong growth of 11.8% due to increased sales outside of the United States.
The Endoscopic Technologies business is performing as anticipated.
Mr. Corasanti continued, "The cash flow of CONMED continues to be
exceptionally strong. This cash flow enabled us to improve our balance sheet
by increasing our cash balance and reducing our senior credit loans while at
the same time reducing the receivable financing program. The net total of all
this improvement was approximately $20 million in the quarter."
Outlook
Joseph Corasanti added, "For all of 2005, based on our first quarter's
sales performance and our estimated sales for the remainder of the year, we
continue to believe that sales will grow approximately 15% above 2004 levels.
Approximately one-half of this total sales increase is expected to come from
internal growth of our product lines and one-half is anticipated from the
effect of the Endoscopic Technologies acquisition for the first nine months of
2005 until its revenues annualize in the fourth quarter of 2005. In addition,
we continue to expect operating cash flow for 2005 to approximate $75 - $80
million. As you are now aware, the SEC has delayed implementation of
expensing stock options. For us, current rules require that we expense stock
options beginning January 1, 2006, so our earnings will not be affected by
this non-cash charge in 2005. Therefore, we now return to our original
diluted earnings per share guidance for 2005 of approximately $1.94 - $1.98,
excluding transition and unusual charges."
"For the second quarter ended June 30, 2005, we anticipate that revenues
will approximate $154 - $157 million and that diluted earnings per share will
be in a range of $0.44 - $0.47, excluding transition and unusual charges",
noted Mr. Corasanti.
Acquisition, and Other Charges
Acquisition - The Company purchased the Endoscopic Technologies product
line from C.R. Bard, Inc. on September 30, 2004 for a purchase price of
approximately $80.0 million. As required by FASB 141, the Company has
recorded the fair value of inventory acquired in the purchase transaction.
Since the fair value of the inventory exceeds the manufacturing cost, as the
initial inventory is sold, cost of sales is higher than what would normally
have been the case. In the first quarter of 2005, this added charge to cost
of sales equaled $0.5 million. Further, during a transition period, CONMED is
purchasing the Endoscopic Technologies finished goods from C.R. Bard at costs
greater than what the Company expects its manufacturing costs to be once
manufacturing is transitioned to CONMED facilities. This difference in cost
for first quarter 2005 is estimated to be $1.8 million and has been recorded
in cost of sales. The Company expects the transition to extend into 2006 in
order to permit an orderly transfer and to be sure that we have sufficient
finished goods inventory on hand to meet our customers' requirements.
Accordingly, we anticipate that we will incur additional cost of sales amounts
on a quarterly basis of $1.5 - $2.0 million until the transition can be
completed We are working closely with the C.R. Bard management to facilitate
the transition of manufacturing to our locations.
Other non-recurring costs in the first quarter of 2005 associated with the
Endoscopic Technologies acquisition including performance compensation and
other integration expenses amounted to $1.4 million.
Cost associated with termination of a product -- CONMED has offered
integrated operating room design and installation for over two years following
the acquisition of the line in November 2002. One of the components of the
system had been a proprietary brand of surgical lights distributed for a
third-party supplier. As previously announced, in the fourth quarter of 2004
the Company concluded that it was a better use of resources to focus research
and development efforts on integrated systems developments. In addition,
limiting customers' options for surgical lights to the Company's proprietary
offering was interfering with our ability to market and sell our integrated
systems to customers who preferred other brands of surgical lights. There are
several other brands of surgical lights, each with specialized features and
benefits that, in some cases, were perceived by customers as better suited to
particular uses or surgeon preferences than the lights offered by the Company.
In order to provide a broader range of choices to customers who preferred the
Company's integration solution, the Company has terminated selling its own
brand of surgical lights and expects to coordinate the installation of the
surgical light choice of the customer when providing CONMED's integration
systems.
CONMED no longer services the installed base of lights purchased from the
Company. In order to maintain customer relationships, and in fairness to
customers who purchased lights from CONMED expecting that CONMED would
maintain its high level of service, the Company initiated a program to replace
all of its surgical lights currently in use. The cost of the program is
estimated to be approximately $4.2 million including purchase and installation
of other manufacturers' lights as well as write-off of existing inventory.
The Company expensed $2.4 million of this amount in the fourth quarter of
2004, and $0.5 million in the first quarter of 2005. It expects additional
charges totaling approximately $1.3 million over the remainder of 2005 as the
replacement program is completed.
Today's Conference Call
CONMED will broadcast its first quarter 2005 conference call live over the
Internet today at 10:00 a.m. Eastern Time. This broadcast can be accessed from
CONMED's web site at http://www.conmed.com. Replays of the call will be made
available through May 5, 2005.
CONMED Profile
CONMED is a medical technology company with an emphasis on surgical
devices and equipment for minimally invasive procedures and monitoring. The
Company's products serve the clinical areas of arthroscopy, powered surgical
instruments, electrosurgery, cardiac monitoring disposables, endosurgery and
endoscopic technologies. They are used by surgeons and physicians in a
variety of specialties including orthopedics, general surgery, gynecology,
neurosurgery, and gastroenterology. Headquartered in Utica, New York, the
Company's 2,800 employees distribute its products worldwide from eleven
manufacturing locations.
Forward Looking Information
This press release contains forward-looking statements based on certain
assumptions and contingencies that involve risks and uncertainties. The
forward-looking statements are made pursuant to the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995 and relate to the
Company's performance on a going-forward basis. The forward-looking
statements in this press release involve risks and uncertainties which could
cause actual results, performance or trends, including the above mentioned
anticipated revenues and earnings, to differ materially from those expressed
in the forward-looking statements herein or in previous disclosures. The
Company believes that all forward-looking statements made by it have a
reasonable basis, but there can be no assurance that management's
expectations, beliefs or projections as expressed in the forward-looking
statements will actually occur or prove to be correct. In addition to general
industry and economic conditions, factors that could cause actual results to
differ materially from those discussed in the forward-looking statements in
this press release include, but are not limited to: (i) the failure of any one
or more of the assumptions stated above, to prove to be correct; (ii) the
risks relating to forward-looking statements discussed in the Company's Annual
Report on Form 10-K for the fiscal year ended December 31, 2004; (iii)
cyclical purchasing patterns from customers, end-users and dealers; (iv)
timely release of new products, and acceptance of such new products by the
market; (v) the introduction of new products by competitors and other
competitive responses; (vi) the possibility that any acquisition (and its
integration) or other transaction may require the Company to reconsider its
financial assumptions and goals/targets; and/or (vii) the Company's ability to
devise and execute strategies to respond to market conditions.
CONMED CORPORATION
CONSOLIDATED STATEMENTS OF INCOME
Three Months Ended March 31, 2004 and 2005
(In thousands except per share amounts)
(unaudited)
2004 2005
Net sales $133,964 $155,859
Cost of sales 63,605 73,046
Cost of sales, nonrecurring - Note A -- 2,338
Gross profit 70,359 80,475
Selling and administrative expense 43,793 52,532
Research and development expense 4,739 5,849
Other expense - Note B -- 1,900
48,532 60,281
Income from operations 21,827 20,194
Interest expense 3,306 3,759
Income before income taxes 18,521 16,435
Provision for income taxes 6,482 5,670
Net income $ 12,039 $10,765
Per share data:
Net income
Basic $.41 $.37
Diluted .40 .36
Weighted average common shares
Basic 29,303 29,127
Diluted 29,992 29,721
Note A - Included in cost of sales in the three months ended March 31,
2005 are approximately $2.3 million in acquisition-related costs.
Note B - Included in other expense in the three months ended March 31,
2005 are $1.4 million in acquisition-related costs and $.5 million of expense
related to the termination of a product offering.
CONMED CORPORATION
CONSOLIDATED CONDENSED BALANCE SHEETS
(in thousands)
(unaudited)
ASSETS
December 31, March 31,
2004 2005
Current assets:
Cash and cash equivalents $4,189 $5,841
Accounts receivable, net 74,593 75,633
Inventories 127,935 132,018
Deferred income taxes 13,733 13,953
Other current assets 2,492 3,106
Total current assets 222,942 230,551
Property, plant and equipment, net. 101,465 101,987
Goodwill and other assets, net 548,418 547,582
Total assets $872,825 $880,120
LIABILITIES AND SHAREHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt $4,037 $4,037
Accrued interest 748 1,962
Other current liabilities 58,276 54,064
Total current liabilities 63,061 60,063
Long-term debt 290,485 277,333
Other long-term liabilities 71,296 76,614
Total liabilities 424,842 414,010
Shareholders' equity:
Capital accounts 226,444 234,322
Retained earnings 227,938 238,703
Accumulated other comprehensive loss (6,399) (6,915)
Total equity 447,983 466,110
Total liabilities and shareholders'
equity $872,825 $880,120
OTHER FINANCIAL INFORMATION
(unaudited, in thousands)
Three months ended
March 31,
2004 2005
Depreciation $2,645 $2,917
Amortization 3,934 4,181
Capital expenditures 1,620 3,985
CONMED CORPORATION
CONSOLIDATED CONDENSED STATEMENT OF CASH FLOWS
(in thousands)
(unaudited)
Three months ended
March 31,
2004 2005
Cash flows from operating activities:
Net income $12,039 $10,765
Adjustments to reconcile net income to net
cash provided by operating activities:
Depreciation and amortization 6,750 7,461
Deferred income taxes 4,248 3,683
Sale of accounts receivable (1,000) (5,000)
Other, net (1,387) (2,678)
Net cash provided by operating activities 20,650 14,231
Cash flow from investing activities:
Purchases of property, plant, and
equipment, net (1,620) (3,985)
Net cash used in investing activities (1,620) (3,985)
Cash flow from financing activities:
Payments on debt (23,178) (13,152)
Net proceeds from common stock issued
under employee plans 8,158 6,053
Other, net (245) (847)
Net cash provided by financing activities (15,265) (7,946)
Effect of exchange rate change on cash and
cash equivalents (284) (648)
Net increase in cash and cash equivalents 3,481 1,652
Cash and cash equivalents at beginning of period 5,986 4,189
Cash and cash equivalents at end of period $9,467 $5,841
CONMED CORPORATION
RECONCILIATION OF REPORTED NET INCOME TO NET INCOME
BEFORE NONRECURRING ITEMS
Three Months Ended March 31, 2004 and 2005
(In thousands except per share amounts)
(unaudited)
2004 2005
Reported net income $12,039 $10,765
Acquisition-related costs included
in cost of sales -- 2,338
Termination of product offering -- 520
Other acquisition related costs -- 1,380
Total other expense -- 1,900
Nonrecurring expense before income taxes -- 4,238
Provision (benefit) for income taxes
on nonrecurring expenses - (1,462)
Net income before nonrecurring items $12,039 $13,541
Per share data:
Reported net income
Basic $0.41 $0.37
Diluted 0.40 0.36
Net income before nonrecurring items
Basic $0.41 $0.46
Diluted 0.40 0.46
Management has provided the above reconciliation of net income before
nonrecurring items as an additional measure that investors can use to compare
operating performance between reporting periods. Management believes this
reconciliation provides a useful presentation of operating performance.
SOURCE CONMED Corporation
 back to top
Related links:
http://www.conmed.com
CONTACT:
Robert Shallish, Chief Financial Officer of
CONMED Corporation, +1-315-624-3206; or Investors: Julie Huang
or Lanie Marcus, or Media: Sean Leous, both of Financial
Dynamics, 212-850-5600, for CONMED Corporation
|
